WO1981000514A1 - New slimming compositions - Google Patents

New slimming compositions Download PDF

Info

Publication number
WO1981000514A1
WO1981000514A1 PCT/FR1980/000132 FR8000132W WO8100514A1 WO 1981000514 A1 WO1981000514 A1 WO 1981000514A1 FR 8000132 W FR8000132 W FR 8000132W WO 8100514 A1 WO8100514 A1 WO 8100514A1
Authority
WO
WIPO (PCT)
Prior art keywords
escin
mucopolysaccharides
weight
cream
compositions
Prior art date
Application number
PCT/FR1980/000132
Other languages
French (fr)
Inventor
J Thorel
Original Assignee
J Thorel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J Thorel filed Critical J Thorel
Priority to AU62229/80A priority Critical patent/AU6222980A/en
Publication of WO1981000514A1 publication Critical patent/WO1981000514A1/en
Priority to DK175081A priority patent/DK175081A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof

Definitions

  • the present invention relates to new slimming compositions.
  • slimming compositions resulting, as we will see experimentally, not only a thinning, but also a mobilization of fat, resulting in real weight loss.
  • mucopolysaccharides used alone in the absence of escin. These are biochemical precursors of the fundamental substance of connective tissues, capable of attacking the sclero-hyaline tissue which encapsulates the cellulite nodules.
  • the mucopolysaccharides therefore modify the structure of the nodules, by first dissociating the sclerotic framework by deep hydration, then secondly, giving rise to a sort of rejuvenation of the connective tissue. But this action turns out, most often of short duration, and in many many subjects, of very limited effectiveness.
  • the escin associated, according to the present invention causes in ten days of cutaneous applications, an accelerated mobilization, c of the lipids, by bringing them up from the deep dermis towards the epidemic , thanks mainly it seems to a very homogeneous dispersion in ' very fine droplets of the com ⁇ positions according to the invention.
  • An ointment is prepared by conventional means having the following percentage weight composition:
  • Weight loss is not only appreciable by weight, but appears by simple visual observation, as confirmed by the photographs taken at regular intervals.
  • the cream can be applied by any conventional means, including the use of certain physical processes such as galvanometric currents.

Abstract

New slimming compositions based on the association of mucopolysaccharides-escin, the derivatives and/or substituted compounds thereof. Application to creams for cutaneous applications.

Description

NOUVELLES COMPOSITIONS AMINCISSANTES NEW SLIMMING COMPOSITIONS
La présente invention a pour objet de nouvelles composi¬ tions amincissantes. Dans ce qui suit, ont désignera par le même adjectif "amincissantes" des compositions entraînant, comme on le verra expérimentalement, non seulement un amin¬ cissement, mais également une mobilisation des graisses, entraînant un réel amaigrissement.The present invention relates to new slimming compositions. In what follows, we will designate by the same adjective "slimming" compositions resulting, as we will see experimentally, not only a thinning, but also a mobilization of fat, resulting in real weight loss.
Dans l'art antérieur de très nombreuses solutions ont été proposées dont l'efficacité est soit limitée, soit liée à des risques certains sur le plan de la santé.In the prior art, numerous solutions have been proposed, the efficacy of which is either limited or linked to certain health risks.
Selon la présente invention, on recourt à l'association de mucopolysaccharides et d'escine dans les conditions qui' seront ci-dessous définies.According to the present invention, use is made of the combination of mucopolysaccharides and escin under the conditions which will be defined below.
L'art antérieur connait l'usage des mucopolysaccharides employés seuls en 1'absence-d'escine.Ce sont des précurseurs biochimiques de la substance fondamentale des tissus conjonc¬ tifs, susceptibles d'attaquer le tissu sclêro-hyalin qui en¬ capsule les nodules cellulitiques. Les mucopolysaccharides modifient donc la structure des nodules, en dissociant, dans un premier temps, la trame sclérotique par hydratation pro¬ fonde, puis dans un second temps, en donnant lieu a une sor¬ te de rajeunissement du tissu conjonctif. Mais cette action se révèle, le plus souvent de courte durée, et chez de nom- breux sujets, d'une efficacité fort limitée.The prior art knows the use of mucopolysaccharides used alone in the absence of escin. These are biochemical precursors of the fundamental substance of connective tissues, capable of attacking the sclero-hyaline tissue which encapsulates the cellulite nodules. The mucopolysaccharides therefore modify the structure of the nodules, by first dissociating the sclerotic framework by deep hydration, then secondly, giving rise to a sort of rejuvenation of the connective tissue. But this action turns out, most often of short duration, and in many many subjects, of very limited effectiveness.
LOr on a constaté de façon particulièrement surprenante que l'association des mucopolysaccharides avec l'escine et/ ou ses dérivés et substitués, entraînait un renforcement, -. une accélération et une prolongation du processus engagé par les mucopolysaccharides. En particulier, on mentionne ci-des sous des tests qui font apparaître, ce que confirme la pho¬ tographie, une mobilisation des graisses se traduisant par l'amincissement ou amaigrissement, ce qui n'a jamais été at- teint dans l'art antérieur .dans des délais aussi brefs et, en particulier, avec des mucopolysaccharides en l'absence d'escine. On constate que l'escine associée, selon la pré¬ sente invention, aux mucopolysaccharides, entraine en une dizaine de jours d'applications cutanées, une mobilisation , c accélérée des lipides, en les faisant remonter du derme pro¬ fond vers 1'épidémie, grâce principalement semble-t-il à une dispersion très homogène en' gouttelettes très fines des com¬ positions conformes à l'invention.LOr it was found in a particularly surprising way that the association of mucopolysaccharides with escin and / or its derivatives and substituted, led to a reinforcement, -. an acceleration and a prolongation of the process initiated by the mucopolysaccharides. In particular, mention is made below of tests which show, which is confirmed by the photography, a mobilization of fats resulting in thinning or slimming, which has never been achieved in the art. anterior .with such short delays and, in particular, with mucopolysaccharides in the absence of escin. It is noted that the escin associated, according to the present invention, with the mucopolysaccharides, causes in ten days of cutaneous applications, an accelerated mobilization, c of the lipids, by bringing them up from the deep dermis towards the epidemic , thanks mainly it seems to a very homogeneous dispersion in ' very fine droplets of the com¬ positions according to the invention.
On a notamment des résultats particulièrement significa¬ tifs avec des préparations pour applications cutanées conte-Particularly significant results have been obtained with preparations for skin applications containing
20 nant de 1 à 10% en poids de mucopolysaccharides et de 0,1 a20 from 1 to 10% by weight of mucopolysaccharides and from 0.1 to
5% en poids d'escine. Les tests comparatifs ont été menés notamment avec les mêmes proportions de mucopolysaccharides, avec ou sans escine.5% by weight of escin. The comparative tests were carried out in particular with the same proportions of mucopolysaccharides, with or without escine.
Pour mieux faire comprendre les caractéristiques techni- 5 ques et les avantages de la présente invention, on va en dë-To better understand the technical features and advantages of the present invention, we will discuss
.crire un exemple de réalisation, étant bien entendu que ce-' lui-ci n'est pas limitatif quant à son mode de mise en oeu¬ vre et aux applications qu'on peut en faire..crire an exemplary embodiment, it being understood that this- 'he is not limited as to its oeu¬ mode setting fever and applications that can make.
On prépare une pommade par les moyens classiques ayant la composition pondérale suivante en pourcentage :An ointment is prepared by conventional means having the following percentage weight composition:
Mucopolysaccharides ("Base EAC 20") 4Mucopolysaccharides ("Base EAC 20") 4
Escine 1Escin 1
Monostéarate de glycérol ("Cutina GMS") , coadjuvant • d'émulgateur 35 Base autoémulsionnante ("Emulgade f") Myristate d'isopropyle Lanoline (du Codex français)
Figure imgf000004_0001
Stéarine T/P 1Glycerol monostearate ("Cutina GMS"), coadjuvant • of emulsifier 35 Self-emulsifying base ("Emulgade f") Isopropyl myristate Lanolin (from the French Codex)
Figure imgf000004_0001
Stearin T / P 1
Huile de vaseline 18Vaseline oil 18
Conservateur ("Kathon") 0,57Conservative ("Kathon") 0.57
Triéthanolamine 0,5Triethanolamine 0.5
Sorbitol à 70 % 2,5Sorbitol 70% 2.5
Aspartate de magnésium . 0,01Magnesium aspartate. 0.01
Aspartate de potassium 0,01Potassium aspartate 0.01
Parfum ("981 Chem") 0,3Perfume ("981 Chem") 0.3
Eau déminéralisée Q.S. pour 100Demineralized water Q.S. for 100
Les mucopolysaccharides ici utilisés, connus dans le corn merce sous la marque "Base EAC 20", répondent à la composi¬ tion très approximative et non limitative suivante, donnée ici pour fixer les idées, en pourcentage pondéral :The mucopolysaccharides used here, known in corn merce under the brand "Base EAC 20", respond to the following very approximate and non-limiting composition, given here to fix ideas, in weight percent:
Héparine 50 à 65Heparin 50 to 65
Sulfate d'héparine 10 à 15Heparin sulfate 10 to 15
Sulfate de chondroltine B 10 à 15Chondroltin B sulfate 10 to 15
Acide hyaluronique 5 à 15Hyaluronic acid 5 to 15
Sulfate de chondroltine C moins de 10Chondroltin sulphate C less than 10
Sulfate de chondroltine A moins de 10Chondroltin sulfate A less than 10
. Chlorure de sodium traces. Traces of sodium chloride
Les essais et tests suivants ont été réalisés à l'aide de la crème ainsi obtenue.The following tests and tests were carried out using the cream thus obtained.
1) Essai de toxicité aiguë par voie orale chez le rat : tolérance parfaite. 2) Essai de tolérance oculaire chez le lapin : la crème administrée à l'état pur n'a provoqué qu'une très légère irritation réversible et prévisible en raison de la sévéri¬ té de l'administration et de la nature même du produit.1) Acute oral toxicity test in rats: perfect tolerance. 2) Eye tolerance test in rabbits: the cream administered in the pure state caused only a very slight reversible and predictable irritation due to the severity of the administration and the very nature of the product.
3) Essai d'irritation cutanée primaire chez le lapin : tolé¬ rance excellente.3) Primary skin irritation test in rabbits: excellent tolerance.
4) Essai de tolérance cutanée par administrations répétées chez le rat. Le flanc droit rasé est laissé sans traitement le gauche également rasé, recevant lml/kg de crème en onc¬ tion dermique. Un lot a reçu' la crème seule, l'autre la crème de base avec 1% d'escine. Dans les deux cas, on a appliqué la crème une fois par jour pendant dix jours. Après prélèvement de peau la cicatrisation s'est effectuée normalement. Toutes les lectures concernant l'aspect raacros- copique et les lames histologiques ont été faites en aveugle Les résultats en sont les suivants : l'aspect de la peau en cours et en fin de traitement ne présente pas de différence entre les deux flancs dans les deux lots. 5 L'histologie est normale pour tous les échantillons. Sur le plan histoenzymologique, le traitement ne perturbe pas le potentiel enzymatique de la peau.4) Test of skin tolerance by repeated administrations in the rat. The shaved right flank is left untreated, the left also shaved, receiving lml / kg of cream in dermal onc¬ tion. One batch received 'cream alone, the other base cream with 1% of escin. In both cases, the cream was applied once a day for ten days. After skin removal, the healing was carried out normally. All the readings concerning the raacros aspect- copic and histological slides were done in blind The results are as follows: the appearance of the skin during and at the end of treatment does not show any difference between the two flanks in the two batches. 5 Histology is normal for all samples. On the histoenzymological level, the treatment does not disturb the enzymatic potential of the skin.
On en conclut une bonne tolérance de traitement avec ou sans escine.We conclude a good tolerance of treatment with or without escine.
10 En ce qui concerne 1'histochimie, la coloration des lipi¬ des met en évidence dans les échantillons du flanc gauche des animaux du second lot (crème avec escine) , une désorga¬ nisation très nette des substances lipidiques, comparative¬ ment avec les autres témoins, ce qui est très net sur les10 With regard to histochemistry, the coloration of the lipids reveals in the samples of the left flank of the animals of the second batch (cream with escine), a very clear disorganization of the lipid substances, compared with the other witnesses, which is very clear on
15 photographies. Elle est importante dans environ 80 % des prélèvements témoins et une désorganisation minime dans en¬ viron 20 % des cas traités avec les mucopolysaccharides seul et nulle dans les autres cas. 5) En employant la méthode de eigert, on colore au Rouge15 photographs. It is significant in approximately 80% of the control samples and minimal disorganization in approximately 20% of the cases treated with the mucopolysaccharides alone and zero in the other cases. 5) Using the eigert method, we color in Red
„n Oil Red les fibres élastiques. Les lipides mis en évidence ont un aspect et une localisation différents très nettement marqués entre témoins et échantillons sans escine d'une part et échantillons soumis à l'association mucopolysaccharides et escine d'autre part.„ N Oil Red elastic fibers. The lipids highlighted have a very clearly marked appearance and localization between controls and samples without escin on the one hand and samples subjected to the combination of mucopolysaccharides and escin on the other hand.
»_ Ceci confirme bien chez 1'animal,comme on l'a vérifié de même chez l'homme, les effets observés grâce à la mobilisa¬ tion des lipides mentionnée ci-dessus.This confirms well in animals, as has been verified in humans, the effects observed thanks to the mobilization of lipids mentioned above.
"6) Chez l'homme les tests ont été menés sur 50 personnes. L'interprétation statistique ne peut d'ores et déjà en être"6) In humans, the tests were conducted on 50 people. Statistical interpretation cannot already be done.
,. considérée comme définitive, 'mais selon cette première sé¬ rie de tests, on parvient à une conclusion favorable sur plus des deux tiers des sujets traités, pour ce qui est de l'activité de la crème. Les tests ont été menés avec des traitements de 10 Jours, 15 Jours, et 30 Jours en constatant un effet d'autant plus poussé que le traitement a été plus,. considered final, 'but according to this first series of tests, a favorable conclusion is reached on more than two thirds of the subjects treated, as regards the activity of the cream. The tests were carried out with 10-day, 15-day, and 30-day treatments, and found that the effect was greater the longer the treatment.
35 long, mais on observe, par rapport au traitement aux mucopo¬ lysaccharides seuls, une accélération très nette et une pro¬ longation des effets en plus de l'augmentation notable de de l'activité déjà signalée ci-dessus. L'amincissement est donc particulièrement remarquable et l'on note comme chez l'animal cette intense mobilisation des substances lipidi¬ ques remontant du derme profond vers l'ëpiderme. On n'a re¬ levé aucun effet secondaire significatif sur quelque plan que ce soit et notamment ni en tolérance orale, ni en toxi¬ cité, ni en ce qui concerne les indices d'irritation cuta¬ née et oculaire primaire.35 long, but we observe, compared to the treatment with mucopolysaccharides alone, a very marked acceleration and a prolongation of the effects in addition to the notable increase in of the activity already reported above. The thinning is therefore particularly remarkable and we note, as in animals, this intense mobilization of lipidic substances going up from the deep dermis towards the epidermis. No significant side effect has been detected on any plan whatsoever and in particular neither in oral tolerance, nor toxicity, nor with regard to the indices of primary skin and eye irritation.
L'amaigrissement est non seulement appréciable pondérale- ment, mais apparait à la simple observation visuelle comme le confirment les photographies prises à intervalles régu¬ liers.Weight loss is not only appreciable by weight, but appears by simple visual observation, as confirmed by the photographs taken at regular intervals.
Dans tous les cas mentionnés ci-dessus, comme en pratique la crème peut être appliquée par tous moyens classiques, y inclus le recours à certains procédés physiques tels que lescourants galvanomêtriques.In all the cases mentioned above, as in practice the cream can be applied by any conventional means, including the use of certain physical processes such as galvanometric currents.
OMFI OMFI

Claims

REVENDICATIONS
1) Compositions amincissantes contenant de l'escine caracté risée par l'association de mucopolysaccharides avec l'esci¬ ne, ses dérivés et/ou substitués. 2) Compositions selon la revendication 1, caractérisées par le fait qu'elles contiennent de 1 à 10% en poids de mucopo¬ lysaccharides.1) Slimming compositions containing escin characterized by the association of mucopolysaccharides with escin, its derivatives and / or substituted. 2) Compositions according to claim 1, characterized in that they contain from 1 to 10% by weight of mucopo¬ lysaccharides.
3) Compositions selon l'une des revendications 1 ou 2 carac¬ térisées par le fait qu'elles contiennent de 0,1 à 5 % en poids d'escine ou équivalent.3) Compositions according to one of claims 1 or 2 carac¬ terized in that they contain 0.1 to 5% by weight of escine or equivalent.
4) Crème amincissante pour application cutanée', caractéri¬ sée par le fait qu'elle contient en poids 4 % de mucopoly¬ saccharides et 1 % d'escine ou équivalent. 4) Slimming cream for skin application ' , characterized by the fact that it contains by weight 4% mucopoly¬ saccharides and 1% escin or equivalent.
PCT/FR1980/000132 1979-08-20 1980-08-13 New slimming compositions WO1981000514A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU62229/80A AU6222980A (en) 1979-08-20 1980-08-13 New slimming compositions
DK175081A DK175081A (en) 1980-08-13 1981-04-15 SLIMPING PREPARATIONS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7920930 1979-08-20
FR7920930A FR2463617A1 (en) 1979-08-20 1979-08-20 NOVEL SLIMMING COMPOSITIONS BASED ON MUCOPOLYSACCHARIDES AND ESCINE

Publications (1)

Publication Number Publication Date
WO1981000514A1 true WO1981000514A1 (en) 1981-03-05

Family

ID=9228941

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1980/000132 WO1981000514A1 (en) 1979-08-20 1980-08-13 New slimming compositions

Country Status (8)

Country Link
EP (1) EP0034153A1 (en)
JP (1) JPS57501281A (en)
BE (1) BE884849A (en)
FR (1) FR2463617A1 (en)
GR (1) GR82352B (en)
NO (1) NO811326L (en)
PT (1) PT71710B (en)
WO (1) WO1981000514A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102658A (en) * 1985-07-19 1992-04-07 National Research Development Corporation Antibody treatment for adiposity
FR2668061A1 (en) * 1990-10-19 1992-04-24 Thorel Jean Noel Cosmetic compositions for application around the eyes
EP0561195A1 (en) * 1992-03-19 1993-09-22 Shiseido Company Limited An invigorating herbal gel for supple skin
EP1987812A1 (en) * 2007-04-23 2008-11-05 Fibona Health Products GmbH Application of hyaferm for cellulitis adapted to daily rhythms

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2551804B (en) * 2016-06-30 2021-04-07 Cummins Ltd Diffuser for a centrifugal compressor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2047874A6 (en) * 1969-06-10 1971-03-19 Nouvel Lucien
FR2400902A1 (en) * 1977-08-22 1979-03-23 Ana Laboratoires Mucopolysaccharidase-aescin-acetazolamide compsns. - for treating cellulitis and excess fat deposition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2047874A6 (en) * 1969-06-10 1971-03-19 Nouvel Lucien
FR2400902A1 (en) * 1977-08-22 1979-03-23 Ana Laboratoires Mucopolysaccharidase-aescin-acetazolamide compsns. - for treating cellulitis and excess fat deposition

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102658A (en) * 1985-07-19 1992-04-07 National Research Development Corporation Antibody treatment for adiposity
FR2668061A1 (en) * 1990-10-19 1992-04-24 Thorel Jean Noel Cosmetic compositions for application around the eyes
EP0561195A1 (en) * 1992-03-19 1993-09-22 Shiseido Company Limited An invigorating herbal gel for supple skin
US5407677A (en) * 1992-03-19 1995-04-18 Shiseido Co., Ltd. Invigorating herbal gel for supple skin
EP1987812A1 (en) * 2007-04-23 2008-11-05 Fibona Health Products GmbH Application of hyaferm for cellulitis adapted to daily rhythms

Also Published As

Publication number Publication date
GR82352B (en) 1984-12-13
JPS57501281A (en) 1982-07-22
PT71710A (en) 1980-09-01
FR2463617B1 (en) 1982-02-05
BE884849A (en) 1980-12-16
FR2463617A1 (en) 1981-02-27
PT71710B (en) 1981-07-09
EP0034153A1 (en) 1981-08-26
NO811326L (en) 1981-04-15

Similar Documents

Publication Publication Date Title
BE1004157A5 (en) PRODUCT INCLUDING BODY PARTS OF SILICON COMBINED WITH ACTIVE SUBSTANCE cosmetically.
DE10010113B4 (en) Native sponge collagen, process for its isolation and its use, as well as native nanoparticulate sponge collagen, process for its preparation and its use
WO1988009654A1 (en) Composition containing extract of mulberry tree
FR2536277A1 (en) NOVEL ANTI-ACNE COMPOSITION BASED ON BENZOYL PEROXIDE AND AT LEAST ONE OTHER ACTIVE INGREDIENT
FR2743813A1 (en) STABLE GELIFIED COMPOSITION WITH HIGH ELECTROLYTE CONTENT
JPS59500129A (en) Sebum-inhibiting cosmetic agent containing long-chain alkanol and antioxidant
JP4308472B2 (en) Highly unsaponifiable matter and method of using the same
EP0586392A1 (en) Method for separating a vegetable compound.
US5993857A (en) Cosmetic skin cleanser based on natural active substances
JP2003527411A (en) Method for preparing a high pressure / high shear dispersion containing a physiologically active ingredient
JPS5883648A (en) Lanolin acid copper and local composition
EP0651990B1 (en) Composition based on C12-C20 esters for make-up removal
CA3164351A1 (en) Method for obtaining an aqueous extract of lavender, compositions comprising such an extract and their cosmetic uses
EP0650717A1 (en) Water-in-oil emulsions containing polyols and their use in cosmetology
FR2706298A1 (en) Cosmetic or dermatological composition in the form of a stable oil-in-water emulsion containing at least one vegetable oil consisting of at least 40% of linoleic acid triglycerides.
FR2782923A1 (en) Transforming cosmetic composition into film, for use as face mask, involves mixing composition with at least one alginate salt, and mixing resulting mixture with calcium salt
WO1981000514A1 (en) New slimming compositions
FR2498928A1 (en) PRODUCT AND METHOD OF TREATMENT FOR HAIR GROWTH
EP0035919A2 (en) Composition for treating the hair
FR2618351A1 (en) Transparent gelled emulsions and process for obtaining them
EP0300842A1 (en) Pharmaceutical or cosmetic composition containing hydroquinone and kojic acid in liposomes
CA1314815C (en) Nail emollient compound
JP3162962B2 (en) Hair restoration
JP2909995B2 (en) Antioxidant
JP5817085B1 (en) Hair dye composition

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU BR DK JP NO SU US

AL Designated countries for regional patents

Designated state(s): AT CH DE GB LU NL SE

WWP Wipo information: published in national office

Ref document number: 1980901503

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1980901503

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1980901503

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1980901503

Country of ref document: EP